Influence of the Combined Use of Pazopanib and Gastric Acid Suppressants on Patients With Sarcoma

Background: This study evaluated the impact of the combined use of pazopanib hydrochloride (PAZ) and gastric acid suppressants (AS) on the progression-free survival and safety of Japanese patients with sarcoma. Methods: A retrospective study of 99 patients with sarcoma who received PAZ treatment between 2012 and 2020 was conducted. Results: Of these patients, 77 received PAZ and AS (AS combination group) and 22 received PAZ only (non-AS group). The median progression-free survival of the AS group was 116 days, and that of the non-AS group was 403 days (no significant difference; P = 0.361). A confounding factor analysis suggested that sex might influence outcomes; however, AS use alone did not result in a significant difference in outcomes. Adverse effects were observed in 84% of the AS group and 68% of the non-AS group. Conclusions: Co-administration of PAZ and AS did not affect the prognosis or safety of patients.